Open an account

Clene

CLNN · NASDAQ

$3.73+$0.44 (+13.37%)TodayMarket closed ·
Prev close $3.29

About CLNN

Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. The company is headquartered in Salt Lake City, Utah and currently employs 79 full-time employees. The company went IPO on 2018-08-27. The CSN therapeutics are comprised of atoms of transition elements that, when assembled in nanocrystal form, possess unusually high, unique catalytic activities that do not present in those same elements in bulk form. CNM-Au8, the lead drug asset, is a concentrated aqueous suspension of catalytically active, clean-surfaced, faceted gold nanocrystals for the treatment of ALS, MS, and PD. CNM-Au8's mechanism of action targets mitochondrial dysfunction by catalyzing the production of nicotinamide adenine dinucleotide. Its CNM-ZnAg is an antiviral and antibacterial agent comprised of zinc (Zn2+) and silver (Ag+) ions in an aqueous solution to treat infectious disease and to provide immune support for symptom resolution.

Employees
78
Headquarters
Salt Lake City, Utah
Listed
Aug 27, 2018
Sector
Health Care
Industry
Biotechnology
Website
clene.com

CLNN key statistics

Market cap
53.02M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
98.46K
Volume
202.02K
Open price
$3.52
High today
$4.05
Low today
$3.20
52 Week high
$13.50
52 Week low
$3.02

Clene (CLNN) at a glance

Clene (CLNN) last traded at $3.73, with a market cap of 53.02M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $3.20 and $4.05. The current price is 16.7% above the day's low and 7.9% below its high.

Volume so far is 202.02K shares, above the average of 98.46K shares a day.

Over the past year Clene has ranged from $3.02 to $13.50, and now sits 7% of the way up that range.

Clene met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$1.08 per share against an estimate of -$0.3754.

The average analyst price target is $32.84, 780.5% above the current price, from 3 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 3 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 7 analystsAvg $32.84
Low
$20.20
Now
$3.73
High
$52.50

CLNN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 52.9% on average.

  1. Q3 FY24: reported -$1.22 per share against an estimate of -$1.35
  2. Q4 FY24: reported -$1.86 per share against an estimate of -$0.969
  3. Q1 FY25: reported -$0.09 per share against an estimate of -$0.969
  4. Q2 FY25: reported -$0.78 per share against an estimate of -$0.4828
  5. Q3 FY25: reported -$0.85 per share against an estimate of -$0.5916
  6. Q4 FY25: reported -$0.88 per share against an estimate of -$0.5977
  7. Q1 FY26: reported -$0.27 per share against an estimate of -$0.6494
  8. Q2 FY26: reported -$1.08 per share against an estimate of -$0.3754

CLNN news

  • Press releaseGlobe Newswire

    A Micro-Cap Biotech Just Cleared a Milestone Most Never Reach

  • Press releaseGlobe Newswire

    Novel Patented Myelin Drug-Discovery Strategy Targets Massive Unmet Need in Multiple Sclerosis

  • Vandana Singh

    Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug

  • Vandana Singh

    Mirum Pharmaceuticals Rally Reflects Confidence In Late-Stage Liver Disease Assets

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseACCESS Newswire

    Clene Inc. Chief Executive Officer Rob Etherington to Present at the Investor Summit Virtual on June 10, 2025

  • Press releaseACCESS Newswire

    Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11

Similar companies

Companies in the same industry as Clene

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.